| Name | Redx Pharma |
|---|---|
| Epic | REDX |
| Isin | GB00BSNB6S51 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 15.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £58.35 | Debt ratio | n/a |
| Shares in issue | 388.99 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -156.04 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -9.9 | 52-week high / low | 4.25p / 36.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Redx Pharma |
|---|---|
| Address | Block 33, Mereside, Alderley Park, United Kingdom, SK10 4TG |
| Telephone | +44 (0)1625 469900 |
| Website | http://redxpharma.com |
| Director | Position |
|---|---|
| Ms Natalie Berner | Non-Executive Director |
| Mr Joseph Anderson | Non-Executive Director |
| Mrs Jane Griffiths | Non-Executive Chairman |
| Mr Lisa Anson | Chief Executive Officer |
| Mr Peter Presland | Independent Non-Executive Director |
| Mr Rob Scott | Independent Non-Executive Director |
| Dr Bernhard Kirschbaum | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 30/09/23 | 30/09/22 | 30/09/21 |
| Intangible asssets and goodwill | 0.39 | 0.4 | 0.41 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 2.33 | 3.1 | 3.73 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 5.21 | 5.5 | 6.23 |
| Cash and equivalents | 18.09 | 53.85 | 29.55 |
| Other current assets and asset held for resale | n/a | 0.03 | 0.03 |
| Total of all assets | 25.64 | 62.48 | 39.55 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 21.01 | 27.2 | 9.59 |
| Long term liabilities | 1.27 | 1.95 | 16.82 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 22.28 | 29.16 | 26.41 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 3.35 | 33.32 | 13.13 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 3.35 | 3.35 | 2.75 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -113.83 | -81.31 | -64.23 |
| Share premium account | 99.5 | 99.5 | 66.3 |
| Total equity | 3.35 | 33.32 | 13.13 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -33.82 | -16.27 | -19.75 |
| Pre-tax profit | -32.79 | -17.8 | -21.44 |